A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer

Fabio Puglisi, Giancarlo Bisagni, Mariangela Ciccarese, Caterina Fontanella, Teresa Gamucci, Luigi Leo, Annamaria Molino, Rosa Rita Silva, Paolo Marchetti

Research output: Contribution to journalReview articlepeer-review

Abstract

To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.

Original languageEnglish
Pages (from-to)2589-2602
Number of pages14
JournalFuture Oncology
Volume12
Issue number22
DOIs
Publication statusPublished - Nov 1 2016

Keywords

  • angiogenesis
  • bevacizumab
  • breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer'. Together they form a unique fingerprint.

Cite this